{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:09Z","timestamp":1761520089158,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clcc.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T23:45:48Z","timestamp":1490312748000},"page":"410-415.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)"],"prefix":"10.1016","volume":"16","author":[{"given":"Fabio","family":"Gelsomino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Spallanzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pettorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Reggiani Bonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Meduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianrocco","family":"Manco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2017.03.011_bib1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1365-2168.2002.02196.x","article-title":"Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands","volume":"89","author":"Kapiteijn","year":"2002","journal-title":"Br J Surg"},{"key":"10.1016\/j.clcc.2017.03.011_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.38937.646400.55","article-title":"Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study","volume":"333","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2017.03.011_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ejca.2013.03.006","article-title":"Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge","volume":"49","author":"Engelen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2017.03.011_bib6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.03.011_bib7","first-page":"CD006041","article-title":"Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer","author":"De Caluw\u00e9","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clcc.2017.03.011_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(07)70202-4","article-title":"Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer","volume":"8","author":"O'Neill","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","article-title":"Neoadjuvant treatment response as an early response indicator for patients with rectal cancer","volume":"30","author":"Park","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial","volume":"16","author":"R\u00f6del","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib12","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","article-title":"Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04","volume":"32","author":"O'Connell","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv248","article-title":"Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial","volume":"107","author":"Allegra","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2017.03.011_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.02.037","article-title":"Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer","volume":"76","author":"Crane","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2017.03.011_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2011.06.008","article-title":"Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer\u2014a two stage phase II clinical trial","volume":"102","author":"Resch","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-011-9250-0","article-title":"A\u00a0phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer","volume":"15","author":"Gasparini","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.clcc.2017.03.011_bib20","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","article-title":"Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)","volume":"30","author":"Dewdney","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijrobp.2008.04.065","article-title":"Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer","volume":"73","author":"Bertolini","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2017.03.011_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.clcc.2017.03.011_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/fon.15.248","article-title":"Effective targeting of colorectal cancer cells using TORC1\/2 kinase inhibitors in\u00a0vitro and in\u00a0vivo","volume":"12","author":"Zhang","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib25","first-page":"1567","article-title":"Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer","volume":"35","author":"Hecht","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2017.03.011_bib26","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2017.03.011_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2017.03.011_bib28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.03.011_bib29","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","volume":"31","author":"Domingo","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2017.03.011_bib31","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/sj.onc.1208715","article-title":"Enhanced radiation damage of tumor vasculature by mTOR inhibitors","volume":"24","author":"Shinohara","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.clcc.2017.03.011_bib32","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","article-title":"Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials","volume":"29","author":"Valentini","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.clcc.2017.03.011_bib33","article-title":"Neoadjuvant rectal cancer (RC) score to predict survival: potential surrogate endpoint for early-phase trials","volume":"32","author":"Yothers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2017.03.011_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.03.011_bib36","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-11-3210","article-title":"Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers","volume":"18","author":"Imamura","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2017.03.011_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suronc.2013.02.001","article-title":"KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis","volume":"22","author":"Clancy","year":"2013","journal-title":"Surg Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib38","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","article-title":"KRAS and combined KRAS\/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy","volume":"23","author":"Chow","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2017.03.011_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1677\/ERC-10-0126","article-title":"mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours","volume":"18","author":"Kasajima","year":"2011","journal-title":"Endocr Relat Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816302651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816302651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:04:03Z","timestamp":1761519843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002816302651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1533002816302651"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2017.03.011","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}